

PX'Therapeutics to open a new cGMP cell culture production facility

Grenoble, France, December 21st 2010 – PX'Therapeutics SA (formerly known as Protein'eXpert) is pleased to announce the opening of an additional cGMP production facility dedicated to mammalian cell culture. The French regulatory authority (AFSSAPS) has just authorized manufacturing operations including the production of biotechnology products, immunology products and extracted products from animal or human origin. This new facility will allow cell banking as well as small scale production and release of protein batches intended for preclinical/clinical use and niche market (orphan disease, cell therapy). The extension of the company's production capabilities is part of its development strategy and will definitely mark its ambition to support therapeutic antibody development. Today, PX'Therapeutics can indeed provide an integrated service offer including generation of murine monoclonal antibody, humanization of therapeutic antibody, development of stable recombinant cell lines and clinical manufacturing.

About PX'Therapeutics

PX'Therapeutics, located in Grenoble and Lyon (France) and with a sales office in Cambridge (MA, USA), offers early stage research and cGMP manufacturing contracts focusing on the development of protein therapeutics, monoclonal antibodies and recombinant vaccines. PX'Therapeutics proposes custom programs targeting the development of monoclonal antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development or small scale clinical manufacturing.

PX'Therapeutics has been playing a key role in the discovery, development and production of target or therapeutic proteins, with over 600 projects performed so far. The company has then accumulated a specific and acknowledged expertise in the field of difficult-to-express proteins and developed trusted relationships with more than 160 biotech/pharmaceutical partners and clients in Europe, North America and Japan. As part of its subsidiary PROMISE ADVANCED PROTEOMICS created in July 2010, PX'Therapeutics also now offers absolute quantification services based upon PSAQ™ technology.

Contact

Christelle Dagoneau

Business Development Director

+33 4 38 02 36 50

ChristelleDagoneau@px-therapeutics.com

www.px-therapeutics.com